{"id":123011,"title":"Avacta Group PLC (AIM:AVCT) Update on timing of preliminary results","publisher":"Share Talk","author":"sharetalk","published":"2025-05-27T09:51:09+00:00","modified":"2025-05-27T09:51:09+00:00","canonical_url":"https://www.share-talk.com/avacta-group-plc-aimavct-update-on-timing-of-preliminary-results/","markdown_url":"https://www.share-talk.com/avacta-group-plc-aimavct-update-on-timing-of-preliminary-results.md","json_url":"https://www.share-talk.com/avacta-group-plc-aimavct-update-on-timing-of-preliminary-results.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","Christina Coughlin","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Dr Christina Coughlin","Europe","LG Chem Life Sciences","Michelle Morrow","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","Share Talk","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/03/AVCT-7-MARCH.webp?fit=1200%2C800&quality=80&ssl=1","format":"news","language":"en-GB","content":"**Avacta Therapeutics (AIM: AVCT),** a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for year ended December 31, 2024 will now be published on June 4, 2025 as the Group’s auditors have been unable to finalise the audit work connected to the disposal of Launch Diagnostics, which completed post period end, by the originally planned date of May, 29 2025. The Group was notified of this development on May 23, 2025.\n\nThere is no impact to Avacta’s financial position and cash runway.\n\n**Christina Coughlin**, **Chief Executive Officer** and **Brian Hahn, Chief Financial Officer**, will now deliver the planned live presentation via Investor Meet Company at 11:00 BST on June 4, 2025.\n\nThe presentation is open to all existing and potential shareholders.\n\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:\n\n[https://www.investormeetcompany.com/avacta-group-plc/register-investor.](https://www.investormeetcompany.com/avacta-group-plc/register-investor.)\n\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\n\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until June 4 at 09:00 BST, or at any time during the live presentation.\n\nThe Company will also post the results presentation on its website at the following page: [https://avacta.com/investors/investor-resources/.](https://avacta.com/investors/investor-resources/.)\n\n-Ends –\n\nFor further information from Avacta Group plc, please contact:\n\n**Avacta Group plc**\n\nMichael Vinegrad, Group Communications\n\nDirector\n\n[https://avacta.com/](https://avacta.com/)"}